Skip to main content
SpringerLink
Log in

Treatment of Systemic Fungal Infections in Older Patients

Achieving Optimal Outcomes

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Systemic fungal infections are an increasing problem in older adults. For several of the endemic mycoses, this increase is the result of increased travel and leisure activities in areas endemic for these fungi. Immunosuppressive agents, care in an intensive care unit, and invasive devices all contribute to infection with opportunistic fungi. Treatment of systemic fungal infections is usually with an azole or amphotericin B. The preferred regimen depends on the specific fungal infection, the site and the severity of the infection, the state of immunosuppression of the patient and the possible toxicities of each drug for a specific patient. In older adults, drug-drug interactions between the azoles and drugs commonly prescribed for older persons may lead to serious toxicity, and absorption of itraconazole can be problematic. Amphotericin B is associated with significant nephrotoxicity, especially in older adults with pre-existing renal disease, and infusion-related adverse effects. Newer lipid formulations of amphotericin B can obviate some of these toxicities, but their role in the treatment of systemic fungal infections in older adults has not yet been clarified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Kauffman CA. Fungal infections. Clin Geriatr Med 1992; 8: 777–91

    PubMed  CAS  Google Scholar 

  2. Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29: 231–7

    Article  PubMed  CAS  Google Scholar 

  3. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981–5

    Article  PubMed  CAS  Google Scholar 

  4. Kauffman CA, Hajjeh R, Chapman S. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000; 30: 684–7

    Article  PubMed  CAS  Google Scholar 

  5. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279–85

    Article  PubMed  CAS  Google Scholar 

  6. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413–7

    Article  PubMed  CAS  Google Scholar 

  7. Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22: 46–50

    Article  PubMed  CAS  Google Scholar 

  8. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine 1986; 65: 143–53

    Article  PubMed  CAS  Google Scholar 

  9. Bradsher RW. Clinical considerations in blastomycosis. Infect Dis Clin Pract 1992; 1: 97–104

    Google Scholar 

  10. Chapman SW, Lin AC, Hendricks A, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997; 12: 219–28

    PubMed  CAS  Google Scholar 

  11. Kauffman CA. Endemic mycoses in older adults. Infect Dis Clin Pract 1995; 4: 41–5

    Article  Google Scholar 

  12. Chapman SW, Bradsher RW, Campbell GD, et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30: 679–83

    Article  PubMed  CAS  Google Scholar 

  13. Dismukes WE. Bradsher RW, Cloud GC, et al. Itraconazo1e therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489–97

    Article  PubMed  CAS  Google Scholar 

  14. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20: 267–71

    Article  PubMed  CAS  Google Scholar 

  15. Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher dose fluconazole. Clin Infect Dis 1997; 25: 200–5

    Article  PubMed  CAS  Google Scholar 

  16. Dismukes WE, Cloud G, Bowles C, et al. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985; 103: 861–72

    Google Scholar 

  17. Wheat J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997; 76: 339–54

    Article  CAS  Google Scholar 

  18. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688–95

    Article  PubMed  CAS  Google Scholar 

  19. McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23: 996–1001

    Article  PubMed  CAS  Google Scholar 

  20. Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332: 1077–82

    Article  PubMed  CAS  Google Scholar 

  21. Leake JAD, Mosley DG, England B, et al. Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996–1997. J Infect Dis 2000; 181: 1435–40

    Article  PubMed  CAS  Google Scholar 

  22. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658–61

    Article  PubMed  CAS  Google Scholar 

  23. Galgiani JN, Catanzaro A, Cloud GA, et al. Randomized double-blind comparison of oral fluconazole and itraconazole for progressive non-meningeal coccidioidomycosis. Ann Intern Med 2000; 133: 676–86

    PubMed  CAS  Google Scholar 

  24. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119: 28–35

    PubMed  CAS  Google Scholar 

  25. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124: 305–10

    PubMed  CAS  Google Scholar 

  26. Kauffman CA, Hedderwick S. Opportunistic fungal infections: filamentous fungi and cryptococcosis. Geriatrics 1997; 52: 40–9

    PubMed  CAS  Google Scholar 

  27. Stockstill MT, Kauffman CA. A comparison of tuberculous and cryptococcal meningitis. Arch Neurol 1983; 40: 81–5

    Article  PubMed  CAS  Google Scholar 

  28. Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179: 449–54

    Article  PubMed  CAS  Google Scholar 

  29. Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis. Arch Neurol 1984; 41: 216–7

    Article  PubMed  CAS  Google Scholar 

  30. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115: 737–40

    Article  Google Scholar 

  31. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis. In press

  32. Saag MS, Graybill JR, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710–8

    Article  PubMed  CAS  Google Scholar 

  33. Hedderwick S, Kauffman CA. Opportunistic fungal infections: superficial and systemic candidiasis. Geriatrics 1997; 52: 50–9

    PubMed  CAS  Google Scholar 

  34. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of can-didemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164–70

    Article  PubMed  CAS  Google Scholar 

  35. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499–511

    PubMed  CAS  Google Scholar 

  36. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995; 155: 2429–35

    Article  PubMed  CAS  Google Scholar 

  37. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122–8

    Article  PubMed  CAS  Google Scholar 

  38. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886–9

    PubMed  CAS  Google Scholar 

  39. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662–78

    Article  PubMed  CAS  Google Scholar 

  40. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325–30

    Article  PubMed  CAS  Google Scholar 

  41. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30: 14–8

    Article  PubMed  CAS  Google Scholar 

  42. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30: 19–24

    Article  PubMed  CAS  Google Scholar 

  43. Jacobs LG. Fungal urinary tract infections in the elderly: treatment guidelines. Drugs Aging 1996; 8: 89–96

    Article  PubMed  CAS  Google Scholar 

  44. Leu H-S, Huang C-T. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20: 1152–7

    Article  PubMed  CAS  Google Scholar 

  45. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805

    Article  PubMed  CAS  Google Scholar 

  46. Binder RE, Faling J, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61: 109–24

    Article  CAS  Google Scholar 

  47. Washburn RG, Kennedy DW, Begley MG, et al. Chronic fungal sinusitis in apparently normal hosts. Medicine (Baltimore) 1988; 67: 231–47

    CAS  Google Scholar 

  48. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696–709

    Article  PubMed  CAS  Google Scholar 

  49. Hiemenz JR, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22Suppl. 2: S133–44

    Article  PubMed  CAS  Google Scholar 

  50. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–6

    Article  PubMed  CAS  Google Scholar 

  51. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol 1997; 39: 143–89

    Article  PubMed  CAS  Google Scholar 

  52. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72

    Article  PubMed  CAS  Google Scholar 

  53. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653–7

    Article  PubMed  CAS  Google Scholar 

  54. Barone JA, Moscovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862–5

    PubMed  CAS  Google Scholar 

  55. Stevens DA. Itraconazole in cyclodextrin solution. Pharmaco-therapy 1999; 19: 603–11

    CAS  Google Scholar 

  56. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphoter-icin B. Clin Infect Dis1995; 20: 755–61

    Article  PubMed  CAS  Google Scholar 

  57. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–18

    Article  PubMed  CAS  Google Scholar 

  58. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–96

    Article  PubMed  CAS  Google Scholar 

  59. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998: 27: 296–302

    Article  PubMed  CAS  Google Scholar 

  60. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–71

    Article  PubMed  CAS  Google Scholar 

  61. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402–7

    Article  PubMed  CAS  Google Scholar 

  62. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmaco-economic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476–83

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, University of Michigan Medical School, Michigan, USA

    Carol A. Kauffman

  2. Royal Victoria Hospital, Belfast, Northern Ireland

    Sara A. Hedderwick

Authors
  1. Carol A. Kauffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara A. Hedderwick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol A. Kauffman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kauffman, C.A., Hedderwick, S.A. Treatment of Systemic Fungal Infections in Older Patients. Drugs & Aging 18, 313–323 (2001). https://doi.org/10.2165/00002512-200118050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118050-00002

Keywords

Search

Navigation